Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017
| Autor: | Felix Y. Feng, Megan Daly, Paul T. Spellman, Timur Mitin, Reshma Jagsi, Paul Okunieff, Abhishek A. Solanki, Charles C. Hsu, Charles R. Thomas, Louis S. Constine, Bradford S. Hoppe, Sunil Krishnan, J. Martin Brown, Dean A. Shumway, Chelsea C. Pinnix, Natalie A. Lockney, Matthew M. Harkenrider, Heiko Enderling, Richard Tuli, Lisa A. Kachnic, Katherine Casey-Sawicki, James W. Welsh, Susan J. Knox, Susan Galbraith, David Raben, Fran Laurie, Robert G. Bristow, Roy H. Decker, Tony J. C. Wang, Greg Yothers, Jerry J. Jaboin, Thomas J. Fitzgerald, David T. Marshall, H. Charles Manning, Nima Nabavizadeh, Steven E. Finkelstein, Chul S. Ha |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Cancer Research medicine.medical_specialty medicine.medical_treatment 03 medical and health sciences 0302 clinical medicine Quality of life (healthcare) Neoplasms medicine Humans Combined Modality Therapy Medical physics Liquid biopsy Radiation Injuries Strategic planning Protocol (science) Radiotherapy business.industry Clinical study design Cancer medicine.disease Radiation therapy 030104 developmental biology Oncology Organ Specificity 030220 oncology & carcinogenesis Quality of Life Radiation Oncology business |
| Zdroj: | Clinical Cancer Research. 24:3500-3509 |
| ISSN: | 1557-3265 1078-0432 |
| DOI: | 10.1158/1078-0432.ccr-17-3202 |
| Popis: | The Radiation Therapy Committee of SWOG periodically evaluates its strategic plan in an effort to maintain a current and relevant scientific focus, and to provide a standard platform for future development of protocol concepts. Participants in the 2017 Strategic Planning Workshop included leaders in cancer basic sciences, molecular theragnostics, pharmaceutical and technology industries, clinical trial design, oncology practice, and statistical analysis. The committee discussed high-priority research areas, such as optimization of combined modality therapy, radiation oncology–specific drug design, identification of molecular profiles predictive of radiation-induced local or distant tumor responses, and methods for normal tissue-specific mitigation of radiation toxicity. The following concepts emerged as dominant questions ready for national testing: (i) what is the role of radiotherapy in the treatment of oligometastatic, oligorecurrent, and oligoprogressive disease? (ii) How can combined modality therapy be used to enhance systemic and local response? (iii) Can we validate and optimize liquid biopsy and other biomarkers (such as novel imaging) to supplement current response criteria to guide therapy and clinical trial design endpoints? (iv) How can we overcome deficiencies of randomized survival endpoint trials in an era of increasing molecular stratification factors? And (v) how can we mitigate treatment-related side effects and maximize quality of life in cancer survivors? The committee concluded that many aspects of these questions are ready for clinical evaluation and example protocol concepts are provided that could improve rates of cancer cure and quality of survival. Clin Cancer Res; 24(15); 3500–9. ©2018 AACR. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|